The FDA issued an emergency use authorization for remdesivir as a COVID-19 treatment May 1, stipulating that the drug only be used to treat hospitalized COVID-19 patients who are using ventilators or have low blood oxygen levels. On Aug. 28, the agency expanded remdesivir’s emergency use authorization to allow for all hospitalized COVID-19 patients, regardless of case severity, to be treated with the antiviral drug.
“We’re not finished with remdesivir,” Mr. O’Day told CNBC.
Mr. O’Day said Gilead began clinical trials exploring intravenous remdesivir in outpatient settings in September.
He also disclosed the drugmaker began testing the drug in an inhaled form in July.
“If one could do it without an IV, right to the site of where you get this replication of the virus in the lungs, we’re also hopeful that you might be able to treat outside the hospital and prevent patients from ever going to the hospital,” Mr. O’Day told CNBC.
More articles on pharmacy:
Gilead expands oncology portfolio, acquires Immunomedics for $21B
NIH testing blood thinners as COVID-19 treatment
8 considerations to take when preparing for COVID-19 vaccine distribution
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
